| Name | Title | Contact Details |
|---|
TheraSim, Inc is a Durham, NC-based company in the Software and Internet sector.
Discover and list the best local classes and curated experiences in your community. Thousands of classes and workshops in cooking, calligraphy, woodworking, yoga, dance, photography, sewing, glassblowing, and city tours in your city. Share your skills....
Lightning AI allows researchers, data scientists, and software engineers to build, share and iterate on highly scalable, production-ready AI apps using the tools and technologies of their choice, regardless of their expertise. To solve any kind of AI problem from research to deployment and production-ready pipelines, users can simply group components of their choice into a Lightning App and customize the underlying code as needed. Lightning Apps can then be republished back into the community for future use, or kept private in users personal libraries. Lightning AI combines a wide variety of extant tools into a modular, intuitive platform for building AI applications in research, enterprise and personal contexts. It is the foundation of the growing Lightning ecosystem, which provides developers with a suite of ready-to-use tools and required infrastructure and compute resources, as well as community support for building AI applications. Lightning AI was founded in 2019 and is based in New York, New York.
ENow is a Microsoft Silver Independent Software Vendor focused on helping organizations implement the latest Microsoft technologies and building software tools that simplify the job of IT administrators. Our innovative systems management software provides robust monitoring and reporting features for all key components of your Microsoft infrastructure, including Exchange, Active Directory, SharePoint and Lync—all delivered in our award winning personalized dashboards, so that everybody in your company benefits.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.